Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology

Effects of Glucagon-like Peptide-1 Drugs in Parkinson's Disease: A Meta-Analysis

GLP-1 Therapies Weekly Brief ↗PubMed ↗DOI ↗

Updated

Abstract

This meta-analysis evaluates the efficacy and safety of glucagon-like peptide-1 receptor agonists (GLP-1 RAs) in Parkinson's disease.

  • Type 2 diabetes and Parkinson's disease share pathways related to insulin resistance and neuroinflammation.
  • GLP-1 RAs may offer neuroprotective effects based on preclinical studies.
  • Conflicting results have been reported in clinical trials regarding the use of GLP-1 RAs in Parkinson's disease.
  • The analysis distinguishes between symptomatic relief and potential modification of the disease.

Simplified

Full Text

Full text is available at the source.
View Full Text ↗

Funding

Competing interests

0 of 10
authors report competing interests
10 report none
PubMed
No competing interests reported.

Related papers

Feb '26
Effectiveness and safety of diabetes drugs called GLP-1 receptor agonists in Parkinson's disease
top 10% journal
cited by 2 papers
journal article
Sep '25
GLP-1 receptor drugs and their link to Parkinson's disease progression: a combined analysis of clinical trials
top 10% journal
journal article
May '26
Effectiveness and safety of GLP-1 receptor drugs in Parkinson's disease
top 30% journal
systematic review
Mar '26
Effectiveness and Safety of Diabetes Drugs That Activate GLP-1 Receptors in Parkinson’s Disease
top 20% journal
systematic review
Mar '26
Glucagon-Like-Peptide-1 Receptor Agonists and Their Effects on Mental Health Outcomes: A Review and Analysis
journal article
Apr '25
Effectiveness and safety of glucagon-like peptide-1 drugs for Parkinson's disease
top 50% journal
systematic review
Apr '26
Effectiveness of GLP-1 receptor drugs in Parkinson's disease: a review and comparison of clinical trials
top 30% journal
cited by 1 paper
journal article
Mar '25
Effectiveness and safety of GLP-1 drugs in Parkinson's disease: a review of clinical trials
top 30% journal
cited by 6 papers
systematic review

What Lands in Your Inbox Each Week:

  • 📚7 fresh studies
  • 📝plain-language summaries
  • ✅direct links to original studies
  • 🏅top journal indicators
  • 📅weekly delivery
  • 🧘‍♂️always free

Recent issues from the glp-1 therapies brief

issue #48
Stop the drug, regain the weight: pooled data puts the average rebound at 7%
2 days ago7 studies
issue #47
The brain region that explains why blocking and activating the same receptor both cause weight loss
1 week ago7 studies
issue #46
GLP-1 drugs linked to lower depression and bipolar disorder risk in large genetic study
2 weeks ago7 studies
issue #45
Stopping GLP-1 drugs linked to higher depression and anxiety risk in type 2 diabetes patients
3 weeks ago7 studies
issue #44
Tirzepatide cut all-cause mortality by more than half compared to semaglutide in a 47,000-patient study
4 weeks ago7 studies
issue #43
Semaglutide linked to 21% lower psychiatric hospitalization risk in bipolar disorder patients
5 weeks ago7 studies
issue #42
Tirzepatide users lost 14.7% of body weight vs. 10.8% with semaglutide — but Black and Hispanic patients were overrepresented in the lowest-response group
6 weeks ago8 studies
issue #41
New obesity drug survodutide cut weight by 13% vs 5.4% for placebo in 725 patients
7 weeks ago7 studies
issue #40
GLP-1 users had 3x higher risk of aspiration pneumonia after stroke surgery
8 weeks ago7 studies
issue #39
Semaglutide linked to reduced cigarette craving in 24 smokers
9 weeks ago7 studies
explore the archive
See more issues from the glp-1 therapies brief